Physician profile
Mark P Brigham
NPI 1093758096
$599.53
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $133.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $284.99 | 2019-2020 | |
| Bioventus LLC | $77.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $71.34 | 2019-2020 | |
| Smith+Nephew, INC. | $63.66 | 2019 | |
| Avanos Medical | $28.33 | 2019 | |
| Trice Medical, INC. | $21.05 | 2019 | |
| Amgen INC. | $17.47 | 2019 | |
| Depuy Synthes Sales INC. | $17.11 | 2019 | |
| Ermi LLC | $13.25 | 2019 | |
| Heraeus Medical, LLC. | $4.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brigham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.